Stephens Investment Management Group LLC trimmed its position in Omnicell, Inc. (NASDAQ:OMCL) by 2.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 319,061 shares of the company’s stock after selling 6,378 shares during the period. Stephens Investment Management Group LLC owned 0.75% of Omnicell worth $22,532,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in OMCL. Meeder Asset Management Inc. increased its position in shares of Omnicell by 930.8% in the 1st quarter. Meeder Asset Management Inc. now owns 402 shares of the company’s stock valued at $26,000 after acquiring an additional 363 shares during the period. Citizens Financial Group Inc RI increased its position in shares of Omnicell by 406.4% in the 1st quarter. Citizens Financial Group Inc RI now owns 1,023 shares of the company’s stock valued at $67,000 after acquiring an additional 821 shares during the period. Sowell Financial Services LLC increased its position in shares of Omnicell by 540.7% in the 1st quarter. Sowell Financial Services LLC now owns 1,134 shares of the company’s stock valued at $74,000 after acquiring an additional 957 shares during the period. Captrust Financial Advisors acquired a new position in shares of Omnicell in the 2nd quarter valued at $86,000. Finally, Smithfield Trust Co. acquired a new position in shares of Omnicell in the 2nd quarter valued at $89,000. 98.99% of the stock is currently owned by hedge funds and other institutional investors.
In other news, CEO Randall A. Lipps sold 3,718 shares of the stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $75.15, for a total transaction of $279,407.70. Following the sale, the chief executive officer now directly owns 152,116 shares of the company’s stock, valued at approximately $11,431,517.40. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 2.63% of the company’s stock.
Shares of OMCL stock traded up $1.15 during mid-day trading on Wednesday, hitting $75.87. 3,285 shares of the stock were exchanged, compared to its average volume of 307,998. The firm has a fifty day moving average of $69.36 and a 200 day moving average of $68.89. Omnicell, Inc. has a 52-week low of $54.24 and a 52-week high of $94.85. The company has a market cap of $3.20 billion, a PE ratio of 67.22, a price-to-earnings-growth ratio of 3.24 and a beta of 0.93.
Omnicell (NASDAQ:OMCL) last posted its earnings results on Tuesday, July 28th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.14. Omnicell had a net margin of 5.42% and a return on equity of 9.21%. The business had revenue of $199.62 million for the quarter, compared to analyst estimates of $182.16 million. During the same period in the prior year, the company posted $0.67 EPS. The company’s revenue for the quarter was down 8.2% on a year-over-year basis. On average, equities research analysts anticipate that Omnicell, Inc. will post 1.48 EPS for the current fiscal year.
OMCL has been the topic of several recent research reports. BidaskClub raised shares of Omnicell from a “sell” rating to a “hold” rating in a report on Friday, September 11th. Stephens initiated coverage on shares of Omnicell in a report on Monday, July 6th. They issued an “overweight” rating and a $90.00 price target on the stock. Piper Sandler lowered their price target on shares of Omnicell from $76.00 to $70.00 and set a “neutral” rating on the stock in a report on Wednesday, July 29th. Cantor Fitzgerald upped their price target on shares of Omnicell from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Finally, Craig Hallum lowered their price target on shares of Omnicell from $102.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, July 29th. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Omnicell currently has an average rating of “Buy” and an average target price of $85.50.
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems.
Featured Story: Catch-Up Contributions
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.